FIMECS Appoints Mr. Tomokazu Saito as Outside Director

News release Download PDF

Kanagawa, Japan, 11, Nov 2022 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Mr. Tomokazu Saito to the role of Outside Director. Mr. Tomokazu Saito is a lawyer and has more than 15 years of industry experience in several private companies as a board of director or an audit & supervisory board member. He will contribute to reinforce a governance, compliance and alliance.

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.

# # #

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261

Back to news list

Return to TOP